Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Considers Reviving Leiner’s U.S. OTC Business

This article was originally published in The Tan Sheet

Executive Summary

NBTY might take a run at the U.S. OTC market, as execs consider bringing back Leiner Health Products' OTC business

You may also be interested in...



Leiner Auction Outcome Will Shift Balance Of Power For Supplement Players

The auction of Leiner Health Products slated for June 9 will reshape the competitive landscape for the dietary supplement market whether the winner is Perrigo or NBTY

Perrigo Fuels “Growth Engine” With Spending On New Product Pipeline

Perrigo plans to file more than 10 abbreviated new drug applications before July this year, President and CEO Joe Papa said Feb. 5

FLAVORx Hopes A Spray-Full Of Pill Glide Helps The Medicine Go Down

FLAVORx designed its flavored Pill Glide Swallowing Sprayto help consumers take difficult-to-swallow or unpleasant-tasting pills

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel